Search Results - "Yang, Xue‐Ning"

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma by Dong, Zhong-Yi, Zhong, Wen-Zhao, Zhang, Xu-Chao, Su, Jian, Xie, Zhi, Liu, Si-Yang, Tu, Hai-Yan, Chen, Hua-Jun, Sun, Yue-Li, Zhou, Qing, Yang, Jin-Ji, Yang, Xue-Ning, Lin, Jia-Xin, Yan, Hong-Hong, Zhai, Hao-Ran, Yan, Li-Xu, Liao, Ri-Qiang, Wu, Si-Pei, Wu, Yi-Long

“…Although clinical studies have shown promise for targeting programmed cell death protein-1 (PD-1) and ligand (PD-L1) signaling in non-small cell lung cancer…”
Get full text

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR -Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study by Zhong, Wen-Zhao, Chen, Ke-Neng, Chen, Chun, Gu, Chun-Dong, Wang, Jun, Yang, Xue-Ning, Mao, Wei-Min, Wang, Qun, Qiao, Gui-Bin, Cheng, Ying, Xu, Lin, Wang, Chang-Li, Chen, Ming-Wei, Kang, Xiaozheng, Yan, Wanpu, Yan, Hong-Hong, Liao, Ri-Qiang, Yang, Jin-Ji, Zhang, Xu-Chao, Zhou, Qing, Wu, Yi-Long

“…To assess the benefits of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as neoadjuvant/adjuvant therapies in locally advanced…”
Get full text

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study by Zhong, Wen-Zhao, Wang, Qun, Mao, Wei-Min, Xu, Song-Tao, Wu, Lin, Shen, Yi, Liu, Yong-Yu, Chen, Chun, Cheng, Ying, Xu, Lin, Wang, Jun, Fei, Ke, Li, Xiao-Fei, Li, Jian, Huang, Cheng, Liu, Zhi-Dong, Xu, Shun, Chen, Ke-Neng, Xu, Shi-Dong, Liu, Lun-Xu, Yu, Ping, Wang, Bu-Hai, Ma, Hai-Tao, Yan, Hong-Hong, Yang, Xue-Ning, Zhou, Qing, Wu, Yi-Long, Wu, Yi-Long, Wang, Qun, Mao, Wei-Min, Wu, Lin, Shen, Yi, Liu, Yong-Yu, Chen, Chun, Cheng, Ying, Xu, Lin, Wang, Jun, Fei, Ke, Li, Xiao-Fei, Li, Jian, Huang, Cheng, Liu, Zhi-Dong, Xu, Shun, Chen, Ke-Neng, Xu, Shi-Dong, Liu, Lun-Xu, Yu, Ping, Wang, Bu-Hai, Ma, Hai-Tao, Wang, Si-Yu, Hu, Jian, Liu, Wei, Li, Wei, Shi, Jian-Hua

“…Cisplatin-based adjuvant chemotherapy is the standard of care for patients with resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT…”
Get full text

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial by Zhong, Wen-Zhao, Wang, Qun, Mao, Wei-Min, Xu, Song-Tao, Wu, Lin, Wei, Yu-Cheng, Liu, Yong-Yu, Chen, Chun, Cheng, Ying, Yin, Rong, Yang, Fan, Ren, Sheng-Xiang, Li, Xiao-Fei, Li, Jian, Huang, Cheng, Liu, Zhi-Dong, Xu, Shun, Chen, Ke-Neng, Xu, Shi-Dong, Liu, Lun-Xu, Yu, Ping, Wang, Bu-Hai, Ma, Hai-Tao, Yang, Jin-Ji, Yan, Hong-Hong, Yang, Xue-Ning, Liu, Si-Yang, Zhou, Qing, Wu, Yi-Long

“…ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved…”
Get full text

Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes by Liu, Si-Yang, Bao, Hua, Wang, Qun, Mao, Wei-Min, Chen, Yedan, Tong, Xiaoling, Xu, Song-Tao, Wu, Lin, Wei, Yu-Cheng, Liu, Yong-Yu, Chen, Chun, Cheng, Ying, Yin, Rong, Yang, Fan, Ren, Sheng-Xiang, Li, Xiao-Fei, Li, Jian, Huang, Cheng, Liu, Zhi-Dong, Xu, Shun, Chen, Ke-Neng, Xu, Shi-Dong, Liu, Lun-Xu, Yu, Ping, Wang, Bu-Hai, Ma, Hai-Tao, Yan, Hong-Hong, Dong, Song, Zhang, Xu-Chao, Su, Jian, Yang, Jin-Ji, Yang, Xue-Ning, Zhou, Qing, Wu, Xue, Shao, Yang, Zhong, Wen-Zhao, Wu, Yi-Long

“…The ADJUVANT study reported the comparative superiority of adjuvant gefitinib over chemotherapy in disease-free survival of resected EGFR -mutant stage II–IIIA…”
Get full text

Toward an Expert Level of Lung Cancer Detection and Classification Using a Deep Convolutional Neural Network by Zhang, Chao, Sun, Xing, Dang, Kang, Li, Ke, Guo, Xiao‐wei, Chang, Jia, Yu, Zong‐qiao, Huang, Fei‐yue, Wu, Yun‐sheng, Liang, Zhu, Liu, Zai‐yi, Zhang, Xue‐gong, Gao, Xing‐lin, Huang, Shao‐hong, Qin, Jie, Feng, Wei‐neng, Zhou, Tao, Zhang, Yan‐bin, Fang, Wei‐jun, Zhao, Ming‐fang, Yang, Xue‐ning, Zhou, Qing, Wu, Yi‐long, Zhong, Wen‐zhao

“…Background Computed tomography (CT) is essential for pulmonary nodule detection in diagnosing lung cancer. As deep learning algorithms have recently been…”
Get full text

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer by Li, Anna, Yang, Jin-Ji, Zhang, Xu-Chao, Zhang, Zhou, Su, Jian, Gou, Lan-Ying, Bai, Yu, Zhou, Qing, Yang, Zhenfan, Han-Zhang, Han, Zhong, Wen-Zhao, Chuai, Shannon, Zhang, Qi, Xie, Zhi, Gao, Hongfei, Chen, Huajun, Wang, Zhen, Wang, Zheng, Yang, Xue-Ning, Wang, Bin-Chao, Gan, Bin, Chen, Zhi-Hong, Jiang, Ben-Yuan, Wu, Si-Pei, Liu, Si-Yang, Xu, Chong-Rui, Wu, Yi-Long

“…amplification, responsible for 20% of acquired resistance to EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC),…”
Get full text

Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status by An, She-Juan, Chen, Zhi-Hong, Su, Jian, Zhang, Xu-Chao, Zhong, Wen-Zhao, Yang, Jin-Ji, Zhou, Qing, Yang, Xue-Ning, Huang, Ling, Guan, Ji-Lin, Nie, Qiang, Yan, Hong-Hong, Mok, Tony S, Wu, Yi-Long

“…Appropriate patient selection is needed for targeted therapies that are efficacious only in patients with specific genetic alterations. We aimed to define…”
Get full text

EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas by Chen, Zhi‐Yong, Zhong, Wen‐Zhao, Zhang, Xu‐Chao, Su, Jian, Yang, Xue‐Ning, Chen, Zhi‐Hong, Yang, Jin‐Ji, Zhou, Qing, Yan, Hong‐Hong, An, She‐Juan, Chen, Hua‐Jun, Jiang, Ben‐Yuan, Mok, Tony S., Wu, Yi‐Long

“…Background. Non‐small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations have mixed responses to tyrosine kinase inhibitors…”
Get full text

Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells by Jiang, Ben-Yuan, Li, Yang-Si, Guo, Wei-Bang, Zhang, Xu-Chao, Chen, Zhi-Hong, Su, Jian, Zhong, Wen-Zhao, Yang, Xue-Ning, Yang, Jin-Ji, Shao, Yang, Huang, Biao, Liu, Yan-Hui, Zhou, Qing, Tu, Hai-Yan, Chen, Hua-Jun, Wang, Zhen, Xu, Chong-Rui, Wang, Bin-Chao, Wu, Shu-Yu, Gao, Cun-Yi, Zhang, Xian, Wu, Yi-Long

“…Leptomeningeal metastases are more common in non-small cell lung cancer (NSCLC) with mutations. The diagnosis is difficult by traditional imaging only, and…”
Get full text

Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy by Zhang, Chao, Yin, Kai, Liu, Si-Yang, Yan, Li-Xu, Su, Jian, Wu, Yi-Long, Zhang, Xu-Chao, Zhong, Wen-Zhao, Yang, Xue-Ning

“…Multiple primary lung cancer (MPLC) remains a tough challenge to diagnose and treat. Although neoadjuvant immunotherapy has shown promising results in early…”
Get full text

Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer by QING ZHOU, ZHANG, Xu-Chao, YANG, Xue-Ning, AN, She-Juan, WANG, Bin-Chao, HUANG, Yi-Sheng, ZHEN WANG, WU, Yi-Long, CHEN, Zhi-Hong, YIN, Xiao-Lu, YANG, Jin-Ji, XU, Chong-Rui, YAN, Hong-Hong, CHEN, Hua-Jun, JIAN SU, ZHONG, Wen-Zhao

“…Our aim was to determine whether abundance of epidermal growth factor receptor (EGFR) mutations in tumors predicts benefit from treatment with EGFR-tyrosine…”
Get full text

EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib by Zhang, Qi, Zhang, Xu-Chao, Yang, Jin-Ji, Yang, Zhen-Fan, Bai, Yu, Su, Jian, Wang, Zheng, Zhang, Zhou, Shao, Yang, Zhou, Qing, Kang, Jin, Ke, E-E, Zhang, Yi-Chen, Dong, Zhong-Yi, Chen, Zhi-Hong, Tu, Hai-Yan, Zhong, Wen-Zhao, Yang, Xue-Ning, Wu, Yi-Long

“…The third-generation EGFR tyrosine kinase inhibitor osimertinib has been approved in many countries to treat advanced NSCLC in patients with the EGFR T790M…”
Get more information

Wait-and-See Treatment Strategy Could be Considered for Lung Adenocarcinoma with Special Pleural Dissemination Lesions, and Low Genomic Instability Correlates with Better Survival by Chen, Ying, Tang, Wen-Fang, Lin, Huan, Bao, Hua, Li, Wei, Wang, Ao, Wu, Xue, Su, Jian, Lin, Jie-Shan, Shao, Yang W., Yang, Xue-Ning, Wu, Yi-Long, Zhong, Wen-Zhao

“…Background This study aimed to evaluate the feasibility of a wait-and-see strategy for non-small cell lung cancer (NSCLC) patients with special pleural…”
Get full text

The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104) by Xu, Song-Tao, Xi, Jun-Jie, Zhong, Wen-Zhao, Mao, Wei-Min, Wu, Lin, Shen, Yi, Liu, Yong-Yu, Chen, Chun, Cheng, Ying, Xu, Lin, Wang, Jun, Fei, Ke, Li, Xiao-Fei, Li, Jian, Huang, Cheng, Liu, Zhi-Dong, Xu, Shun, Chen, Ke-Neng, Xu, Shi-Dong, Liu, Lun-Xu, Yu, Ping, Wang, Bu-Hai, Ma, Hai-Tao, Yan, Hong-Hong, Yang, Xue-Ning, Zhang, Yong-Xing, Yin, Jia-Cheng, Wang, Qun, Wu, Yi-Long

“…Adjuvant gefitinib therapy prolonged disease-free survival in patients with resected early-stage EGFR-mutation positive NSCLC in the ADJUVANT study (CTONG…”
Get more information

Application of indocyanine green fluorescence for precision sublobar resection by Zhang, Chao, Lin, Huan, Fu, Rui, Zhang, Tao, Nie, Qiang, Dong, Song, Yang, Xue‐Ning, Wu, Yi‐Long, Zhong, Wen‐Zhao

“…Background Increasing identification of small pulmonary nodules promotes sublobar resection, but localization and surgical margins of non‐palpable pulmonary…”
Get full text

Randomized Trial of an Improved Drainage Strategy Versus Routine Chest Tube After Lung Wedge Resection by Zhang, Jia-Tao, Dong, Song, Chu, Xiang-Peng, Lin, Shao-Min, Yu, Run-Ying, Jiang, Ben-Yuan, Liao, Ri-Qiang, Nie, Qiang, Yan, Hong-Hong, Yang, Xue-Ning, Wu, Yi-Long, Zhong, Wen-Zhao

“…Patients undergoing thoracic lung wedge resection could benefit from tubeless strategies. However, postoperative pneumothorax is a primary limiting factor for…”
Get full text

Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies by Dong, Zhong-Yi, Zhang, Chao, Li, Yu-Fa, Su, Jian, Xie, Zhi, Liu, Si-Yang, Yan, Li-Xu, Chen, Zhi-Hong, Yang, Xue-Ning, Lin, Jun-Tao, Tu, Hai-Yan, Yang, Jin-Ji, Zhou, Qing, Sun, Yue-Li, Zhong, Wen-Zhao, Wu, Yi-Long

“…Subtype classification of lung adenocarcinoma (LUAD) divides different survivals and therapeutic vulnerabilities; however, little is known about the disease's…”
Get more information

Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer by Kang, Jin, Zhang, Xu-Chao, Chen, Hua-Jun, Zhong, Wen-Zhao, Xu, Yang, Su, Jian, Zhou, Qing, Tu, Hai-Yan, Wang, Zhen, Xu, Chong-Rui, Yang, Xue-Ning, Chen, Zhi-Hong, Wu, Xue, Zhang, Xian, Shao, Yang, Wu, Yi-Long, Yang, Jin-Ji

“…Echinoderm microtubule-associated protein-like 4 ( ) is the canonical anaplastic lymphoma kinase ( ) fusion partner in non-small cell lung cancer (NSCLC), and…”
Get full text

Sublobectomy for stage IA1‐2 invasive lung adenocarcinoma with consolidation tumor ratio ≤ 0.25 by Qi, Yi‐Fan, Qiu, Zhen‐Bin, Zhang, Chao, Fu, Rui, Yang, Xiong‐Wen, Chu, Xiang‐Peng, Chen, Zi‐Hao, Yang, Xue‐Ning, Wu, Yi‐Long, Zhong, Wen‐Zhao

“…Background Sublobectomy for early‐stage non‐small cell lung cancer (NSCLC) remains a matter of debate. This study aimed to discuss the feasibility of…”
Get full text